



SYSCHEM (INDIA) LIMITED
Regd.Off.:Village BARGODAM, Tehsil
Kalka, Distt. Panchkula (Haryana)
Tel.No.:0172-5070472;
CIN:L24219HR1993PLC032195,
Website:www.syschem.in;
Email:info@syschem.in

Ref: SIL/2025-26/INT_BM

Date: 02nd February, 2026

To,
The General Manager
Corporate Relationship Dept.
BSE Limited
PJ Tower, Dalal Street, Mumbai- 400 001

Equity Scrip Code: 531173

Kind Att: Head –Listing Department

Subject: Outcome of the Board meeting as per regulation 33 and 30 of SEBI (Listing Obligations and Disclosure requirements), 2015

Pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company, at its meeting held on **Monday, 02nd February, 2026** at the Corporate Office, which commenced at **11:00 A.M.** and concluded at **3:20 P.M.**, inter alia, considered and approved the following:

- **Unaudited Financial Results:** Pursuant to regulation 30 and 33 of SEBI (Listing Obligations and disclosure requirements), 2015, the Board approved the **Unaudited Financial Results** of the Company for the **quarter and nine months ended December 31, 2025**, along with the **Limited Review Report** issued by the Statutory Auditors of the Company. The results are available at the Company site at https://syschem.in/investors_FINANCIALREPT.html and QR code for the same is:



- **Limited Review Report:** The Statutory Auditors have carried out a limited review of the aforesaid financial results and have expressed an unmodified conclusion. The Unaudited Financial Results along with the Limited Review Report are enclosed herewith.
- **Adoption of Revised Related Party Policy:** Approval of draft revised related party transactions policy of the Company, subject to the approval of Audit Committee as applicable in order to align the Policy with the requirement of **SEBI Circular SEBI/HO/CFD/CFD-PoD-2/P/CIR/2025/135** dated 13th October, 2025 for approval of Related Party Transactions. This disclosure is made in compliance with regulation 30 of SEBI (LODR), 2015.
- **Expansion of Existing Unit:** In view of the tremendous market response to the Company's products, the Board has considered and approved the expansion of its existing plant units. The expansion includes the addition of a new manufacturing unit for **Amoxicillin and Ampicillin**, along with further expansion of the existing **CDF unit** comprising **Cloxacillin Sodium, Dicloxacillin Sodium, and Flucloxacillin Sodium**.

Additionally, the Company will expand its **Effluent Treatment Plant (ETP)** and **Multi-Effect Evaporator (MEE)** to strengthen environmental compliance and support sustainable operations.

This expansion is expected to significantly enhance the Company's manufacturing capacity, operational efficiency, and environmental management capabilities. The details of the expansion of the existing units are as follows:

Particular	Remarks
Nature of Expansion	Expansion of existing Plant
Location	Village Bargodam, Teshil Kalka, Panchkula, 133302
Estimated cost	₹14 crore Approx
Funding	Internal accruals / borrowings
Expected benefits	Increased capacity, operational efficiency, revenue growth
Timeline	Expected commissioning by December, 2026

You are requested to kindly take the above information on record.

This is for your information and record.

Yours Truly
For **Syschem India Limited**

Shikha Kataria
Company Secretary
M.NO:57304

SYSCEM (INDIA) LIMITED

Regd. Office : Village BARGODAM, Tehsil Kalka, Distt. Panchkula (Haryana)

Website : www.syschem.in CIN : L24219HR1993PLC032195

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER, 2025

(Figures in Lakhs)

S No.	Particulars	QUARTER ENDED			NINE MONTHS ENDED		PREV YEAR 31.03.2025 (Audited)
		31.12.2025 (Unaudited)	30.09.2025 (Unaudited)	31.12.2024 (Unaudited)	31.12.2025 (Unaudited)	31.12.2024 (Unaudited)	
1.	Income from Operations						
	(a) Revenue from Operations - Gross	16164.21	11,792.36	9112.60	40632.40	24748.47	38623.10
	(b) Other Income	0.16	1.05	1.62	1.73	2.55	4.24
	Total Income from Operations	16164.37	11793.41	9114.22	40634.14	24751.02	38627.34
2.	Expenses						
	(a) Cost of materials consumed	13284.81	7,990.81	8382.99	31477.08	19281.20	31086.60
	(b) Purchase of Stock in Trade						
	(c) Changes in inventories of Finished Goods, Work-in-Progress and Stock-in-trade	-398.02	1,602.70	-1103.44	1362.08	696.79	-364.59
	(d) Employee benefits expense	288.63	228.57	169.65	708.54	599.98	824.69
	(e) Finance Costs	17.35	0.97	3.79	22.23	7.09	6.60
	(f) Depreciation and amortisation expense	82.44	75.67	67.95	233.79	203.72	294.69
	(g) Excise Duty / GST	2014.59	1,432.06	1336.35	5190.93	3467.35	5455.43
	(g) Other Expenses	378.04	207.91	206.62	720.87	494.91	1222.76
	Total Expenses	15667.85	11538.69	9063.91	39715.53	24751.04	38526.18
3.	Profit/(Loss) before exceptional Items and Tax (1-2)	496.52	254.72	50.31	918.60	-0.02	101.16
4.	Exceptional Items						
5.	Profit before tax (3-4)	496.52	254.72	50.31	918.60	-0.02	101.16
6.	Tax Expense						
	for Current	79.44	64.88		144.32		16.84
	for Deferred						55.15
	for MAT Credit						-16.84
7.	Profit/(Loss) for the period (5-6)	417.08	189.84	50.31	774.28	-0.02	46.01
8.	Share of Profit/(Loss) of associates and joint ventures						
9.	Other Comprehensive Income/(Expense) (net of tax)						
	Items that will not be reclassified to Profit & Loss						
	Items that will be reclassified to Profit & Loss						
10.	Total Comprehensive Income for the period (7+9) (Comprising Profit & Other Comprehensive Income for the period)	417.08	189.84	50.31	774.28	-0.02	46.01
11.	Basic and Diluted Earning Per Share on Net Profit after Tax (in Rupees)	0.96/0.74	0.44/0.34	0.13	1.78/1.37	0.00	0.115/0.109
12.	Paid up Equity Share Capital (Face value Rs.10/- per share)	4351.30	4351.30	3986.30	4351.30	3986.30	4351.30

Notes:

- The above financial results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on 2nd February 2026. The Statutory Auditors have carried out a Limited Audit Review of the above results.
- The Financial Results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of Companies Act, 2013 read with relevant Rules thereunder and in terms of Regulation 33 of SEBI (Listing Obligation and Disclosure)
- Segment Reporting as defined in Accounting Standard 17 is not applicable as the Company is engaged in pharmaceutical business segment.
- Previous period / year figures have been regrouped, wherever necessary, in order to make them comparable.

By Order of the Board

Ranjan Jain

Managing Director

Ranjan Jain

DIN : 00635274

PLACE : CHANDIGARH
DATED : 02-02-2026

SYSCEM (INDIA) LTD.

Director



STAV & CO

CHARTERED ACCOUNTANTS

HOUSE NO. 3130-P, SECTOR 22-D, CHANDIGARH – 160022

(M) 98880 - 55545, email: cavarinder.chauhan@gmail.com

LIMITED AUDIT REVIEW

The Board of Directors,
Syschem (India) Limited,
Village Bargodam, Tehsil Kalka,
Distt. Panchkula – 133 302 [Haryana]

SUB :- LIMITED AUDIT REVIEW FOR THE QUARTER ENDED 31.12.2025.

Dear Sirs,

We have reviewed the accompanying statement of Unaudited Financial Results of **Syschem (India) Limited** ('The Company') for the period ended 31st December, 2025. The Statement being submitted to the Company pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosures Requirements) Regulation, 2015 read with SEBI Circular Dated July 5, 2016.

This statement is the responsibility of the Company's management and has been approved by the Board of Directors at its meeting held on 02nd February, 2026. Our responsibility is to issue a report on these financial statements based on the review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, '*Review of Interim Financial Information performed by the Independent Auditor of the Entity*' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Unaudited Financial Results has been prepared in accordance with applicable Accounting Standards i.e. IND AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosures Requirements) Regulation, 2015 read with SEBI Circular Dated July 5, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S T A V & CO
Chartered Accountants
Firm Registration No. 024510C

VARINDER
R SINGH
(CA VARINDER SINGH)
PARTNER
M.No. 542573

Digitally signed by VARINDER SINGH
DN: c=IN, o=PERS CHAL, st=IN, email=varinder.singh@perschal.com, ou=VARINDER SINGH, cn=VARINDER SINGH
Date: 2026.02.02 14:50:43 +05'30'

Date : 02.02.2026
Place : Chandigarh

UDIN : 26542573QUGZGA9178